The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational planning process to ensure independence, balance, objectivity and scientific rigor for all Continuing Medical Education (CME) activities.
In compliance with the ACCME Standards, each individual in a position to control the content of a CME activity is required to disclose all financial relationships with ACCME defined ineligible companies. All disclosures are reviewed to identify relevant financial relationships and any conflicts of interest are mitigated before the individual can assume their role in the activity.
How to Receive Your CME Certificate (Physicians Only)
Physicians are entitled to receive a CME certificate after completing the Conference evaluation survey. A link to this survey has been emailed to all attendees at the conclusion of the Conference. After submitting the survey, physicians have the option to print or save their CME certificate.
CME certificates will reflect the number of accredited sessions attended. CME accredited activities are designated in the program guide. The deadline for claiming CME credit is December 31, 2022.
How to Receive Your Certificate of Attendance (Non-Physicians)
Non-physicians are entitled to receive a “Certificate of Attendance”. To claim a Certificate of Attendance, non-physicians must first complete the Conference evaluation survey. A survey link has been emailed to all attendees at the conclusion of the Conference. After submitting the survey, attendees may print or save their Certificate of Attendance. The deadline for receiving a Certificate of Attendance is December 31, 2022.
The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IASLC designates this “other activity” (a live conference offered in a hybrid format including recorded virtual participation) for a maximum of 57.25 AMA PRA Category 1 Credit(s)TM.
Goal & Purpose
The IASLC 2022 World Conference on Lung Cancer (WCLC 2022) is the world’s largest international conference for clinicians, researchers and scientists in the field of lung cancer and thoracic oncology. Bringing together lung cancer specialists from around the world and across disciplines, the conference offers opportunities for learning and sharing the latest developments in lung cancer and thoracic malignancy research, prevention, diagnosis, treatment and management. With 20 educational tracks and over 300 global experts as invited speakers, WCLC 2022 provides a robust, comprehensive scientific program encompassing cutting edge knowledge on subjects such as tumor biomarkers, clinical trials, targeted therapies, liquid biopsy, lung cancer screening, immunotherapy, tobacco control and patient advocacy. Sessions include plenaries with live Q&A, expert lectures, panel discussions, oral abstracts and posters.
Target Audience
The IASLC 2022 World Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician assistants.
Learning Objectives
At the conclusion of this activity, participants will be able to:
Examine scientific advances in thoracic cancer including the pathogenesis, biology, and mechanisms of drug interactions that can be used to make evidence-based diagnosis and treatment decisions.
Synthesize cutting edge research from clinical trials and translational studies conducted around the world to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.
Advocate for lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, addressing the quality and value of healthcare, and implementing early screening.
Apply evidence-based recommendations and clinical practice guidelines to diagnose and manage patients.
Collaborate on multidisciplinary teams to improve patient outcomes through patient-centered diagnostic, therapeutic and palliative care.
Engage and empower patients to become active participants in their treatment.
Official Language
The official language of the IASLC 2022 World Conference on Lung Cancer is English.
Disclaimer
The information presented at the IASLC 2022 World Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Conference Newsletter
Subscribe to the Newsletter to receive important information about the upcoming Conference.
